Albairmani Raniah A, Basheer Basheer M, Macky May M, Al Syouti Tala, AlZubaidy Haya, Elfaki Eyman, Kidwai Alweena, Basheer Yousif M, Ahmed Fatma, Salaheldin Mona
Medicine, HMS (Health and Medical Services) Al Garhoud Hospital, Dubai, ARE.
Medicine, HMS (Health and Medical Services) Mirdif Hospital, Dubai, ARE.
Cureus. 2025 Feb 19;17(2):e79334. doi: 10.7759/cureus.79334. eCollection 2025 Feb.
This literature review assesses clinical guidelines for pre-existing diabetes and gestational diabetes mellitus (GDM) in the areas of diagnosis, management, and maternal-fetal outcomes. A structured search was conducted across PubMed and Google Scholar, supplemented by targeted screening of guideline repositories from the American Diabetes Association (ADA), National Institute for Health and Care Excellence (NICE), and World Health Organization (WHO). Included studies and guidelines were selected based on relevance to diagnosis, therapeutic strategies, or maternal-neonatal outcomes, with exclusion criteria applied to non-English publications and non-clinical recommendations. A comparative analysis of guidelines from the ADA, NICE, and WHO was performed to evaluate prevalence, therapeutic approaches, and postpartum management. Early diagnosis, stringent blood glucose control, and multidisciplinary care with the aim to avoid macrosomia, congenital abnormalities, and neonatal hypoglycemia guide the management guidelines. Glycated hemoglobin (HbA1c) (<6.5%) optimization and supplementation with folic acid are critically required prior to conception in all women with previously diagnosed diabetes. Continuous glucose monitoring (CGM) and insulin pump therapy are valued but burdened by availability and access constraints. A postpartum visit with 75 g oral glucose tolerance test (OGTT) at 4-12 weeks is essential for the detection of persistent diabetes. Variation of diagnostic criteria among guidelines reflects the requirement for standardization. Expansion of coverage by insurance for CGM and preconception care is important for providing equal access. The cost-effectiveness of new technologies and health disparities in low-resource settings must be addressed in future research.
本综述评估了关于孕前糖尿病和妊娠期糖尿病(GDM)在诊断、管理及母婴结局方面的临床指南。通过在PubMed和谷歌学术上进行结构化检索,并辅以对美国糖尿病协会(ADA)、英国国家卫生与临床优化研究所(NICE)及世界卫生组织(WHO)指南库的针对性筛选。纳入的研究和指南基于与诊断、治疗策略或母婴结局的相关性进行选择,排除标准适用于非英文出版物和非临床建议。对ADA、NICE和WHO的指南进行了比较分析,以评估患病率、治疗方法及产后管理。早期诊断、严格的血糖控制以及旨在避免巨大儿、先天性异常和新生儿低血糖的多学科护理指导着管理指南。所有先前诊断为糖尿病的女性在受孕前都急需优化糖化血红蛋白(HbA1c)(<6.5%)并补充叶酸。持续葡萄糖监测(CGM)和胰岛素泵治疗虽有价值,但受可用性和获取限制的困扰。产后4 - 12周进行75克口服葡萄糖耐量试验(OGTT)访视对于检测持续性糖尿病至关重要。指南间诊断标准的差异反映了标准化的需求。扩大CGM和孕前护理的保险覆盖范围对于提供平等获取机会很重要。新技术的成本效益以及低资源环境中的健康差异问题必须在未来研究中加以解决。